Provided by Tiger Fintech (Singapore) Pte. Ltd.

ALX Oncology Holdings

1.62
+0.240017.39%
Volume:662.19K
Turnover:1.04M
Market Cap:87.83M
PE:-0.80
High:1.65
Open:1.39
Low:1.38
Close:1.38
52wk High:2.27
52wk Low:0.4040
Shares:54.22M
Float Shares:28.99M
Volume Ratio:1.71
T/O Rate:2.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0202
EPS(LYR):-2.5846
ROE:-104.21%
ROA:-47.78%
PB:1.36
PE(LYR):-0.63

Loading ...

ALX Oncology Appoints Board Member Barbara Klencke, M.d., as Interim Chief Medical Officer

THOMSON REUTERS
·
Sep 12

Shelly Pinto, SVP Finance and CAO, Reports Disposal of Common Shares of ALX Oncology Holdings Inc

Reuters
·
Aug 20

ALX Oncology CEO Jason Lettmann Reports Disposal of Common Shares

Reuters
·
Aug 20

ALX Oncology Initiates Phase 1 Clinical Trial for Promising EGFR-Targeted ADC, ALX2004, in Solid Tumor Treatment

Reuters
·
Aug 19

ALX Oncology Holdings Inc - Initial Safety Data Anticipated in First Half 2026

THOMSON REUTERS
·
Aug 19

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC Alx2004 for the Treatment of Egfr-Expressing Solid Tumors

THOMSON REUTERS
·
Aug 19

ALX Oncology Holdings Inc. Files Initial Beneficial Ownership Statement for Director Daniel J. Curran

Reuters
·
Aug 14

ALX Oncology Holdings Q2 Adj. EPS $(0.44) Beats $(0.45) Estimate

Benzinga
·
Aug 13

BRIEF-ALX Oncology Q2 Basic EPS USD -0.49

Reuters
·
Aug 13

ALX Oncology Holdings Inc - Cash Runway Extended to Q1 2027

THOMSON REUTERS
·
Aug 13

ALX Oncology Holdings Inc. Announces Launch of Phase 1 Trial for ALX2004 in EGFR-Expressing Solid Tumors, First Patient Dosing Expected This Month

Reuters
·
Aug 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 11

ALX Oncology Holdings Inc expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
Aug 09

ALX Oncology Holdings Inc expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
Aug 05

Shelly Pinto, SVP Finance and CAO, Reports Disposal of Common Shares of ALX Oncology Holdings Inc

Reuters
·
Jul 09

Shelly Pinto, SVP Finance and CAO, Reports Disposal of Common Shares in ALX Oncology Holdings Inc

Reuters
·
Jul 02

ALX Oncology Holdings Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 13

ALX Oncology Is Maintained at Buy by UBS

Dow Jones
·
May 21

UBS Adjusts Price Target on ALX Oncology Holdings to $1 From $1.20, Maintains Buy Rating

MT Newswires Live
·
May 21